Developer docs
API playgroundTry for free, no card

Search company profiles

Sensible Diagnostics

Full company profile

uuid000kn88

Namestring
Sensible Diagnostics
Legal namestring
Sensible Diagnostics
Websiteurl
sensibledx.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Sensible Diagnostics is a privately held entity whose name suggests operations in the diagnostics sector, though no substantive business information is available in the source data reviewed. The company's only observable public-facing presence is a Google Sites placeholder page at sensibledx.com marked 'Under Construction,' containing no product descriptions, technology disclosures, team information, customer references, or pricing details. No products or services have been documented; no core technology stack, proprietary features, or platform architecture is described in the source material. The source data includes empty arrays for headcount, funding rounds, partnerships, certifications, awards, patents, management team, and M&A activity, indicating either an early-stage profile or a complete absence of disclosed information.

The company's business model cannot be characterized from the available data: no revenue model, pricing approach, go-to-market motion, distribution channels, or customer segmentation is disclosed. The legal entity name 'Sensible Diagnostics' is confirmed and the company is presumed private based on absence of public listing evidence. Operating status is marked as 'operating' per the source, though the 'Under Construction' website state introduces ambiguity — it may reflect an early-stage website build rather than company inactivity. Ownership, domicile, founding date, and geographic operating footprint are all undisclosed in the available material.

Short descriptiontext

Sensible Diagnostics is a privately held diagnostics-sector entity whose only observable public presence is a placeholder 'Under Construction' website, with no disclosed products, technology, customers, or revenue model in the source data.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
diagnostic testing, clinical diagnostics, molecular diagnostics, diagnostic devices, diagnostic technology
Industry1 code
PRIMARYHLAGADAB
Method Development & Validation (ICH/USP)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
Product category
Clinical Diagnostics
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The company's core offerings cannot be determined from the available source data. The sourced material consists of a Google Sites placeholder page displaying an 'Under Construction' notice with no substantive product, service, or capability information. The company name 'Sensible Diagnostics' suggests an orientation toward diagnostic products, but no specific products or services are described in the input.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Cepheid (a Danaher subsidiary) is a leading molecular diagnostics company with the GeneXpert platform widely deployed in clinical and point-of-care settings. Comparable to a company named Sensible Diagnostics as a benchmark for in-vitro diagnostics product economics, regulatory pathway, and hospital-channel commercialization.

TypeBroad incumbent
Description

bioMérieux is a global in-vitro diagnostics leader across clinical and industrial microbiology, immunoassays, and molecular diagnostics. It is a relevant incumbent benchmark for any company entering diagnostics with respect to menu breadth, regulatory scale, and global distribution.

TypeBroad incumbent
Description

QuidelOrtho specializes in clinical diagnostics, including rapid immunoassays and molecular testing. It is comparable to Sensible Diagnostics as a mid-sized diagnostics player addressing similar hospital and point-of-care customers with assay-based products.

TypeBroad incumbent
Description

Hologic's Diagnostics segment produces molecular assays (e.g., Panther system) and rapid tests across women's health, infectious disease, and respiratory. Comparable as a clinical diagnostics incumbent with a similar assay-based business model and FDA-cleared product portfolio.

5Abbott Diagnostics
TypeBroad incumbent
Description

Abbott is a top-tier diagnostics company with platforms spanning immunoassays, clinical chemistry, molecular, and rapid point-of-care testing (e.g., Binax, ID NOW). Comparable as a broad incumbent defining the competitive landscape any new diagnostics entrant faces.

TypeBroad incumbent
Description

Roche Diagnostics is the largest in-vitro diagnostics company globally, with cobas platforms and a deep assay menu across centralized and decentralized testing. Comparable as the dominant incumbent any diagnostics entrant must differentiate against.

TypeBroad incumbent
Description

BD's Life Sciences and Diagnostic Systems segments include molecular diagnostics, sample preparation, and rapid testing products. Comparable as a broad incumbent with diversified diagnostics offerings and established clinical channel access.

TypeDirect peer
Description

Qiagen is a molecular diagnostics and sample technologies company serving both clinical diagnostics and life science research customers. Comparable to Sensible Diagnostics as a more focused, science-driven diagnostics company whose model centers on consumables and assay kits.

TypeEmerging player
Description

Mesa Labs develops and manufactures quality measurement and diagnostic instruments across clinical and industrial end markets, including sterilization indicators and cold-chain monitoring. Comparable as a smaller, niche diagnostics-adjacent company whose profile resembles what a young Sensible Diagnostics could look like once operational.

TypeEmerging player
Description

GenMark (now part of Roche) developed the ePlex system for syndromic molecular diagnostics prior to acquisition. Comparable as an emerging diagnostics player that built a focused molecular platform and ultimately achieved an incumbent exit — useful reference for a similarly named early-stage diagnostics venture.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights2 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sensible Diagnostics

Clinical Diagnosticssensibledx.com

Sensible Diagnostics is a privately held diagnostics-sector entity whose only observable public presence is a placeholder 'Under Construction' website, with no disclosed products, technology, customers, or revenue model in the source data.

What Sensible Diagnostics does

Sensible Diagnostics is a privately held entity whose name suggests operations in the diagnostics sector, though no substantive business information is available in the source data reviewed. The company's only observable public-facing presence is a Google Sites placeholder page at sensibledx.com marked 'Under Construction,' containing no product descriptions, technology disclosures, team information, customer references, or pricing details. No products or services have been documented; no core technology stack, proprietary features, or platform architecture is described in the source material. The source data includes empty arrays for headcount, funding rounds, partnerships, certifications, awards, patents, management team, and M&A activity, indicating either an early-stage profile or a complete absence of disclosed information.

The company's business model cannot be characterized from the available data: no revenue model, pricing approach, go-to-market motion, distribution channels, or customer segmentation is disclosed. The legal entity name 'Sensible Diagnostics' is confirmed and the company is presumed private based on absence of public listing evidence. Operating status is marked as 'operating' per the source, though the 'Under Construction' website state introduces ambiguity — it may reflect an early-stage website build rather than company inactivity. Ownership, domicile, founding date, and geographic operating footprint are all undisclosed in the available material.

Sensible Diagnostics firmographics

Firmographics
Name
Sensible Diagnostics
Legal name
Sensible Diagnostics
Website
https://sensibledx.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Sensible Diagnostics is a privately held diagnostics-sector entity whose only observable public presence is a placeholder 'Under Construction' website, with no disclosed products, technology, customers, or revenue model in the source data.
Ownership category
akta.pro rank

Sensible Diagnostics industry classification

Industry
Product category
Clinical Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
akta.pro industry
PRIMARYHLAGADAB
Method Development & Validation (ICH/USP)

Keywords

  • Diagnostic testing
  • Clinical diagnostics
  • Molecular diagnostics
  • Diagnostic devices
  • Diagnostic technology

Where Sensible Diagnostics is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Markets served

Sensible Diagnostics business model

Business model
GTM type
B2B
Offering type
Services

Sensible Diagnostics product offering

Product offering

Core offering

The company's core offerings cannot be determined from the available source data. The sourced material consists of a Google Sites placeholder page displaying an 'Under Construction' notice with no substantive product, service, or capability information. The company name 'Sensible Diagnostics' suggests an orientation toward diagnostic products, but no specific products or services are described in the input.

Differentiator

Problem solved

Functional benefit

Sensible Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Sensible Diagnostics partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Sensible Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • Cepheid: Cepheid (a Danaher subsidiary) is a leading molecular diagnostics company with the GeneXpert platform widely deployed in clinical and point-of-care settings. Comparable to a company named Sensible Diagnostics as a benchmark for in-vitro diagnostics product economics, regulatory pathway, and hospital-channel commercialization.
  • bioMérieux: bioMérieux is a global in-vitro diagnostics leader across clinical and industrial microbiology, immunoassays, and molecular diagnostics. It is a relevant incumbent benchmark for any company entering diagnostics with respect to menu breadth, regulatory scale, and global distribution.
  • QuidelOrtho: QuidelOrtho specializes in clinical diagnostics, including rapid immunoassays and molecular testing. It is comparable to Sensible Diagnostics as a mid-sized diagnostics player addressing similar hospital and point-of-care customers with assay-based products.
  • Hologic: Hologic's Diagnostics segment produces molecular assays (e.g., Panther system) and rapid tests across women's health, infectious disease, and respiratory. Comparable as a clinical diagnostics incumbent with a similar assay-based business model and FDA-cleared product portfolio.
  • Abbott Diagnostics: Abbott is a top-tier diagnostics company with platforms spanning immunoassays, clinical chemistry, molecular, and rapid point-of-care testing (e.g., Binax, ID NOW). Comparable as a broad incumbent defining the competitive landscape any new diagnostics entrant faces.
  • Roche Diagnostics: Roche Diagnostics is the largest in-vitro diagnostics company globally, with cobas platforms and a deep assay menu across centralized and decentralized testing. Comparable as the dominant incumbent any diagnostics entrant must differentiate against.
  • Becton, Dickinson and Company (BD): BD's Life Sciences and Diagnostic Systems segments include molecular diagnostics, sample preparation, and rapid testing products. Comparable as a broad incumbent with diversified diagnostics offerings and established clinical channel access.

Direct peers

  • Qiagen: Qiagen is a molecular diagnostics and sample technologies company serving both clinical diagnostics and life science research customers. Comparable to Sensible Diagnostics as a more focused, science-driven diagnostics company whose model centers on consumables and assay kits.

Emerging players

  • Mesa Labs: Mesa Labs develops and manufactures quality measurement and diagnostic instruments across clinical and industrial end markets, including sterilization indicators and cold-chain monitoring. Comparable as a smaller, niche diagnostics-adjacent company whose profile resembles what a young Sensible Diagnostics could look like once operational.
  • GenMark Diagnostics: GenMark (now part of Roche) developed the ePlex system for syndromic molecular diagnostics prior to acquisition. Comparable as an emerging diagnostics player that built a focused molecular platform and ultimately achieved an incumbent exit — useful reference for a similarly named early-stage diagnostics venture.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat1 record

Key risks4 records

Key highlights2 records

Customer concentration

Sensible Diagnostics social profiles

Digital presence

Sensible Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sensible Diagnostics leadership team

Management profile

Number of profiles

Sensible Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sensible Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sensible Diagnostics

What does Sensible Diagnostics do?

The company's core offerings cannot be determined from the available source data. The sourced material consists of a Google Sites placeholder page displaying an 'Under Construction' notice with no substantive product, service, or capability information. The company name 'Sensible Diagnostics' suggests an orientation toward diagnostic products, but no specific products or services are described in the input.

Is Sensible Diagnostics a public or private company?

Sensible Diagnostics is a private company. It is classified as unknown and is currently operating.

When was Sensible Diagnostics founded?

Sensible Diagnostics was founded in -1. It employs 1 to 10 people.

Where is Sensible Diagnostics based?

Sensible Diagnostics is headquartered in Los Angeles, United States, in the North America region.

Who are Sensible Diagnostics's main competitors?

Broad incumbents on record are Cepheid, bioMérieux, QuidelOrtho, Hologic, Abbott Diagnostics, Roche Diagnostics and Becton, Dickinson and Company (BD). Qiagen is listed as a direct peer. Emerging players are Mesa Labs and GenMark Diagnostics.

Does Sensible Diagnostics have an API?

No public API is recorded for Sensible Diagnostics.

What industry is Sensible Diagnostics in?

Sensible Diagnostics's product category is Clinical Diagnostics. Its primary akta.pro industry code is HLAGADAB, Method Development & Validation (ICH/USP). Its NAICS code is 325413.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Towards HealthcarePoint-of-Care Molecular Diagnostics Market to Expand USD 11.03 Bn by 2034The global point-of-care molecular diagnostics market is projected to grow from USD 4.05 billion in 2024 to USD 11.03 billion by 2034, driven by decentralized healthcare demands and advancements in multiplex testing. Key industry activities include strategic acquisitions such as Access Genetics acquiring Sensible Diagnostics and QuidelOrtho planning to acquire LEX Diagnostics to enhance product portfolios.PR NewswireSensible Diagnostics, Inc. announces NIH RADx® award of ~$1 millionSensible Diagnostics, Inc. has been selected by the NIH RADx® Tech program and will receive up to $1 million in non-dilutive milestone-based funding over 3–4 months to accelerate development of a multiplexed PCR respiratory viral panel for point-of-care use. The technology platform was originally developed by Curative Inc., one of the country's largest COVID-19 testing providers during the pandemic. If Sensible successfully meets its Phase 1 deliverables, the company can request a larger second round of non-dilutive funding under the same program.Business Wire BlogCurative Announces Spin-Off of Sensible Diagnostics with their Game-Changing 10-Minute Point-Of-Care PCR Testing PlatformCurative Inc. announced the spin-off of Sensible Diagnostics, which will commercialize a 10-minute point-of-care PCR testing platform. The platform aims to deliver lab-quality PCR results at competitive pricing, targeting retail clinics and urgent care. The company is preparing to launch a Series A funding round.